ArticleScientific reports2025
SpheroidSync as edge cutting transfer strategy for uniform and robust MCF7 spheroids in 3D culture.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Three-dimensional spheroid models in breast cancer: tumor microenvironment complexity, cancer stem cell-driven resistance, and translational model integration.Journal of translational medicine · 2026Review
- From Luminal to Triple Negative: 3D Spheroids Reveal Molecular and Phenotypic Differences Across Breast Cancer Subtypes.International journal of molecular sciences · 2026Article
- Metformin potentiates DSF/Cu-loaded pluronic nanoparticles to improve therapeutic efficacy in triple-negative breast cancer.BMC biotechnology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three-dimensional spheroid models play a crucial role in cancer stem cell (CSC) research and drug screening. However, traditional methods often struggle with issues such as inconsistent shapes, difficulties in nutrient diffusion, and technical complexities. In this study, we introduce the SpheroidSync (SS) method, an innovative approach that combines conventional techniques to create uniform and size-adjustable MCF7 breast cancer spheroids at a very low cost, without the need for special growth factors or supplements. Our research involved culturing MCF7 cells using both the standard methods and the new SS method. We meticulously assessed various factors, including spheroid shape and cell viability, through fluorescent staining, colony formation assays, and gene expression analysis. The results revealed that the SS method produced spheroids that were not only uniform but also showed better structural integrity and maintained viability over time compared to traditional methods. Fluorescent viability tests indicated that SS spheroids consistently exhibited healthy cell viability as evidenced by sustained intracellular esterase activity throughout more extended culture periods. In contrast, spheroids generated through conventional methods exhibited declining viability, characterized by core deterioration and uneven staining. Furthermore, gene expression analysis showed a significant increase in CSC markers in SS spheroids, with CD44 levels rising over 40-fold, ALDH1 increasing more than threefold, CD24 decreasing, and HIF-1α elevating over 11-fold when compared to two-dimensional cultures. This establishes the typical breast CSC characteristics and confirms that a hypoxic environment was effectively created. Notably, as esterase activity declined, we observed an increase in stem cell populations, indicating a successful shift towards a quiescent, stem-like state. In summary, SpheroidSync represents a significant advancement in three-dimensional cancer modeling. It enables the production of uniform spheroids in a cost-effective manner, while ensuring long-term viability and enriching CSC populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.